Stabilis

Midazolam hydrochloride



Noms commerciaux

Benzosed	Equateur, Inde, Vénézuela
Buccolam	Allemagne, Belgique
Crismidor	Colombie
Dalam	Argentine
Dormicum	Afrique du sud, Allemagne, Arabie Saoudite, Argentine, Autriche, Belgique, Colombie, Croatie, Danemark, Egypte, Emirats Arabes Unis , Espagne, Finlande, Grèce, Hongrie, Irlande, Mexique, Pays bas, Pologne, Portugal, Roumanie, Russie, Slovénie, Suède, Suisse, Turquie
Dormipron	Colombie
Dormire	Brésil, Chili
Dormomid	Brésil, Chili
Gobbizolam	Argentine
Hipnazolam	Brésil
Hypnovel	Australie, France, Grande Bretagne, Maroc, Nouvelle Zélande
Induson	Brésil, Colombie
Lamcord	Mexique
Midanium	Pologne
Midasedan	Colombie
Midaselect	Allemagne
Midozor	Mexique
Relacum	Brésil, Colombie, Equateur, Mexique
Sedoz	Colombie
Somnocal	Mexique
Sopodorm	Pologne
Zolamid	Portugal, Turquie
Zolmid	Chili

Stabilité des solutions

		0,03 mg/ml	4°C		72			896
		0,5 mg/ml	24-26°C		36			41
		0,5 mg/ml	39-41°C		36			41

		0,5 mg/ml	4-6°C		36				41
		0,036 mg/ml	21°C		24				350
		0,5 mg/ml	-20°C		14				2376
		0,5 mg/ml	21-25°C		14				2376
		0,5 mg/ml	7-9°C		14				2376
PVC		0,03 mg/ml	4°C		72				896
PVC		0,036 mg/ml	21°C		24				350
PVC		1 mg/ml	20°C-25°C		30				399
PVC		1 mg/ml	22°C-24°C		10				185
PVC		1 mg/ml	4°C		30				399
PVC		1 mg/ml	20-25°C		27				3222
PVC		1 mg/ml	3-4°C		27				3222
PE		0,035 mg/ml	22°C		24				1067
PE		0,035 mg/ml	4°C		24				1067
PE		0,036 mg/ml	21°C		24				350
POF		0,5 mg/ml	2-6°C		30				231
POF		0,5 mg/ml	22°C-24°C		30				231
POF		1 mg/ml	20-25°C		27				3222
POF		1 mg/ml	3-4°C		27				3222
		1 mg/ml	-20°C		365				3989
		1 mg/ml	-20°C	?	365				4201
		1 mg/ml	2-8°C	?	365				4201
		1 mg/ml	23-25°C	?	90				4201
		1 mg/ml	5°C		365				3989
		2 mg/ml	30°C	?	10				5
		2 mg/ml	5°C	?	10				5
		3 mg/ml	20°C		7				401
		3 mg/ml	32°C	?	7				401
		0,4 mg/ml	25°C	?	100				4303
	∅	5 mg/ml	24-26°C		36				41
	∅	5 mg/ml	25°C	?	100				4303
		1 mg/ml	-20°C		365				3989
		1 mg/ml	-20°C	?	365				4201

		1 mg/ml	2-8°C	?	365			4201
		1 mg/ml	23-25°C	?	90			4201
		1 mg/ml	5°C		365			3989

Stabilité en mélange

		2,5 mg/ml	20°C-25°C		Morphine sulfate : 2,5 & 5 mg/ml	14	1492
		0,05 & 5 mg/ml	20°C-25°C		Tirofiban : 50 µg/ml	4	1603
		1 mg/ml	20°C-25°C	?	Palonosetron hydrochloride : 25 µg/ml	4	1975
		0,5 mg/ml	22°C-23°C		Milrinone lactate : 0,2 mg/ml	4	813
		0,1 & 0,5 mg/ml	23°C-25°C		Fentanyl citrate : 20 & 40 µg/ml	3	225
		0,1 & 0,5 mg/ml	23°C-25°C		Morphine sulfate : 0,25 & 1 mg/ml	3	86
		0,1 & 0,5 mg/ml	25°C		Atracurium besylate : 1 & 5 mg/ml	3	865
PVC		0,5 mg/ml	22°C		Morphine tartrate : 1 mg/ml	28	2083
PP		4 mg/ml	22-25°C		Methadone hydrochloride : 0.2 mg/ml	24	1506
PP		1,66 mg/ml	23°C		Ondansetron hydrochloride : 1,33 mg/ml	24	815
PP		3,6 mg/ml	25°C		Clonidine hydrochloride : 0,015 mg/ml Sufentanil citrate : 0,03 mg/ml	7	3705
PP		3,6 mg/ml	25°C		Clonidine hydrochloride : 0,015 mg/ml	7	3705
PP		3,6 mg/ml	25°C		Ketamine hydrochloride : 25 mg/ml	7	3705
PP		3,6 mg/ml	25°C		Sufentanil citrate : 0,03 mg/ml	7	3705
PP		3,6 mg/ml	25°C		Clonidine hydrochloride : 0,015 mg/ml Piritramide : 1 mg/ml Ketamine hydrochloride : 25 mg/ml Lormetazepam : 0,12 mg/ml Sufentanil citrate : 0,03 mg/ml	8	3705
PP		1,2 mg/ml	25°C		Propofol : 6,7 mg/ml Sufentanil citrate : 0,0033 mg/ml	24	4011
PP		0,9 mg/ml	25°C		Propofol : 5 mg/ml Sufentanil citrate : 0,0075 mg/ml Lormetazepam : 0,03 mg/ml	24	4011
PP		1,2 mg/ml	25°C		Remifentanil hydrochloride : 1,7 µg/ml Propofol : 6,7 mg/ml	24	4011
PP		1,66 mg/ml	4°C		Ondansetron hydrochloride : 1,33 mg/ml	24	815
PP		4 mg/ml	22-25°C		Dobutamine hydrochloride : 8 mg/ml	24	1506
PP		0,66 & 5 mg/ml	22°C		Diamorphine hydrochloride : 0,66 & 33 mg/ml	14	1288
PP		0,6 mg/ml	32°C		Fentanyl citrate : 40 µg/ml Scopolamine N-butyl bromide : 0,85 mg/ml	10	1405

		0,6 mg/ml	32°C		Metoclopramide hydrochloride : 0,7 mg/ml Fentanyl citrate : 40 µg/ml	10	1405
		0,66 & 0,9 mg/ml	22°C		Fentanyl citrate : 13 & 38 µg/ml	7	929
		1 mg/ml	25°C		Famotidine : 0,4 mg/ml Hydromorphone hydrochloride : 10 mg/ml	96	2166
		0,66 & 0,9 mg/ml	38°C		Fentanyl citrate : 13 & 38 µg/ml	4	929
		1 mg/ml	4°C		Famotidine : 0,4 mg/ml Hydromorphone hydrochloride : 10 mg/ml	96	2166
		0,66 & 0,9 mg/ml	5°C		Fentanyl citrate : 13 & 38 µg/ml	7	929
		0.1 & 0.5 mg/ml	23°C		Hydromorphone hydrochloride : 2 & 20 mg/ml	23	345
		0.1 & 0.5 mg/ml	4°C		Hydromorphone hydrochloride : 2 & 20 mg/ml	23	345
		0,5 mg/ml	22°C		Morphine tartrate : 1 mg/ml Bupivacaine hydrochloride : 4 mg/ml	28	2083

Facteur influençant la stabilité

					1887
					1415
					301 939
	NaH CO3				150 176 3466 3823
					1887
	PH > 5				186

Compatibilités

		Midazolam hydrochloride : 2,5 mg/ml Alprostadil : 20 µg/ml		4491
		Midazolam hydrochloride : 2,5 mg/ml Alprostadil : 20 µg/ml		4651
		Midazolam hydrochloride : 5 mg/ml Amikacin sulfate : 5 mg/ml		186
		Midazolam hydrochloride : 0.25 & 0.4 mg/ml Aminophylline : 0.72 mg/ml		1888
		Midazolam hydrochloride : 0.05 mg/ml Aminophylline : 0.72 mg/ml		1888
		Midazolam hydrochloride : 2.1 mg/ml Amiodarone hydrochloride : 15 mg/ml		3823
		Midazolam hydrochloride : 1 mg/ml Amiodarone hydrochloride : 4.8 mg/ml		295

		Midazolam hydrochloride : 10 mg/ml Amiodarone hydrochloride : 0,6 >> 9,75 mg/ml		4119
		Midazolam hydrochloride : 10 mg/ml Amiodarone hydrochloride : 12,5 mg/ml		4119
		Midazolam hydrochloride : 1 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611
		Midazolam hydrochloride Amiodarone hydrochloride		3464
		Midazolam hydrochloride : 10 mg/ml Amiodarone hydrochloride : 25 mg/ml		4119
		Midazolam hydrochloride : 5 mg/ml Amoxicillin sodium : 50 mg/ml	∅	186
		Midazolam hydrochloride : 0.05 & 0.4 mg/ml Amoxicillin sodium : 10 mg/ml		1888
		Midazolam hydrochloride : 5 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Midazolam hydrochloride : 5 mg/ml Amoxicillin sodium / clavulanic acid : 20/2 mg/ml	∅	186
		Midazolam hydrochloride : 2 mg/ml Amphotericin B cholesteryl sulfate complex : 0,83 mg/ml		921
		Midazolam hydrochloride : 1 mg/ml Ampicillin sodium : 20 mg/ml		176
		Midazolam hydrochloride : 1 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Midazolam hydrochloride : 2 mg/ml Argatroban : 1 mg/ml		1964
		Midazolam hydrochloride : 0.05 mg/ml Atracurium besylate : 0.5 mg/ml		402
		Midazolam hydrochloride : 0.1 & 0.5 mg/ml Atracurium besylate : 1 & 5 mg/ml		865
		Midazolam hydrochloride : 2.5 mg/ml Atropine sulfate : 0.2 mg/ml	∅	404
		Midazolam hydrochloride : 2 mg/ml Bivalirudin : 5 mg/ml		1944
		Midazolam hydrochloride : 1 mg/ml Bivalirudin : 5 mg/ml		1713
		Midazolam hydrochloride : 1 mg/ml Blinatumomab : 0.125 & 0.375 µg/ml		3976
		Midazolam hydrochloride : 5 mg/ml Bumetanide : 0.5 mg/ml	∅	186
		Midazolam hydrochloride : 2.5 mg/ml Buprenorphine hydrochloride : 0.15 mg/ml	∅	404
		Midazolam hydrochloride : 2.5 mg/ml Butorphanol tartrate : 1 mg/ml	∅	404
		Midazolam hydrochloride : 5 mg/ml Caffeine : 10 mg/ml	∅	3964
		Midazolam hydrochloride : 1 mg/ml Calcium gluconate : 100 mg/ml		176
		Midazolam hydrochloride : 2 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Midazolam hydrochloride : 1 mg/ml Cefazolin sodium : 20 mg/ml		176

		Midazolam hydrochloride : 5 mg/ml Cefepime dihydrochloride : 125 mg/ml		2141
		Midazolam hydrochloride : 2 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Midazolam hydrochloride : 0.5 mg/ml Cefmetazole sodium : 100 mg/ml		93
		Midazolam hydrochloride : 1 mg/ml Cefotaxime sodium : 20 mg/ml		176
		Midazolam hydrochloride : 5 mg/ml Cefotaxime sodium : 10 mg/ml	∅	186
		Midazolam hydrochloride : 2 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Midazolam hydrochloride : 2 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Midazolam hydrochloride : 5 mg/ml Ceftazidime : 125 mg/ml		2141
		Midazolam hydrochloride : 5 mg/ml Ceftazidime : 83.3 mg/ml		1759
		Midazolam hydrochloride : 1 mg/ml Ceftazidime : 20 mg/ml		176
		Midazolam hydrochloride : 2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Midazolam hydrochloride : 2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Midazolam hydrochloride Ceftobiprole medocaril sodium		4650
		Midazolam hydrochloride : 1 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Midazolam hydrochloride : 1 mg/ml Cefuroxime sodium : 15 mg/ml		176
		Midazolam hydrochloride : 0.05 >> 0.4 mg/ml Cefuroxime sodium : 7.5 mg/ml		1888
		Midazolam hydrochloride : 1.67 mg/ml Chlorpromazine hydrochloride : 16.67 mg/ml	∅	404
		Midazolam hydrochloride : 1 mg/ml Cimetidine hydrochloride : 15 mg/ml		176
		Midazolam hydrochloride : 1.67 mg/ml Cimetidine hydrochloride : 100 mg/ml	∅	404
		Midazolam hydrochloride : 0.05 & 0.25 mg/ml Cimetidine hydrochloride : 0.8 mg/ml		1888
		Midazolam hydrochloride : 0.2 mg/ml Ciprofloxacin lactate : 2 mg/ml		285
		Midazolam hydrochloride : 5 mg/ml Ciprofloxacin lactate : 2 mg/ml	∅	186
		Midazolam hydrochloride Cisatracurium besylate		3601
		Midazolam hydrochloride : 1 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Midazolam hydrochloride : 2.1 mg/ml Cisatracurium besylate : 5 mg/ml		3823
		Midazolam hydrochloride : 1 mg/ml Clindamycin phosphate : 9 mg/ml		176

		Midazolam hydrochloride : 2.1 mg/ml Clonazepam : 0.2 mg/ml		3823
		Midazolam hydrochloride : 1 mg/ml Clonidine hydrochloride : 0,018 mg/ml		2018
		Midazolam hydrochloride : 3.6 mg/ml Clonidine hydrochloride : 0.015 mg/ml		3705
		Midazolam hydrochloride : 2.1 mg/ml Clonidine hydrochloride : 0.012 mg/ml		3823
24		Midazolam hydrochloride : 5 mg/ml Clonidine hydrochloride : 0.015 mg/ml	∅	186
		Midazolam hydrochloride : 5 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Midazolam hydrochloride : 5 mg/ml Co-trimoxazole : 0.8/4 mg/ml	∅	186
		Midazolam hydrochloride Daunorubicin/cytarabine liposomale : 0,4 mg/mL		4654
2		Midazolam hydrochloride : 5 mg/ml Defibrotide : 8 mg/ml		3728
		Midazolam hydrochloride : > 0,25 mg/ml Dexamethasone sodium phosphate : > 0,25 mg/ml		1637
		Midazolam hydrochloride : 0.625 mg/ml Dexamethasone sodium phosphate : 0.5 mg/ml		1901
		Midazolam hydrochloride : 0,5 & 1,5 mg/ml Dexamethasone sodium phosphate : 0,44 & 1,33 mg/ml		1971
		Midazolam hydrochloride : 1 mg/ml Dexamethasone sodium phosphate : 4 mg/ml		176
		Midazolam hydrochloride : 0,25 mg/ml Dexamethasone sodium phosphate : 0,25 mg/ml		1637
		Midazolam hydrochloride : 5 mg/ml Dexamethasone sodium phosphate : 4 mg/ml	∅	186
		Midazolam hydrochloride : 1,2 mg/ml Dexamethasone sodium phosphate : 0,2 >>0,4 mg/ml		4404
		Midazolam hydrochloride : 0,66 & 5 mg/ml Diamorphine hydrochloride : 0,66 & 33 mg/ml		1288
?		Midazolam hydrochloride : 2,1 mg/ml Diclofenac : 3 mg/ml		3823
		Midazolam hydrochloride : 1 mg/ml Digoxin : 100 µg/ml		176
		Midazolam hydrochloride : 2 mg/ml Diltiazem hydrochloride : 1 mg/ml		314
		Midazolam hydrochloride : 25 mg/ml Dimenhydrinate : 25 mg/ml	∅	404
		Midazolam hydrochloride : 2.5 mg/ml Diphenhydramine hydrochloride : 25 mg/ml	∅	404
		Midazolam hydrochloride Disodium glucose-1-phosphate tetrahydrate		4802
8		Midazolam hydrochloride : 1 mg/ml Dobutamine hydrochloride : 2 mg/ml		176
		Midazolam hydrochloride : 1 mg/ml Dobutamine hydrochloride : 4 mg/ml		295
		Midazolam hydrochloride : 2 mg/ml Dobutamine hydrochloride : 4 mg/ml		314

		Midazolam hydrochloride : 4 mg/ml Dobutamine hydrochloride : 8 mg/ml	▲	1506
		Midazolam hydrochloride : 4 mg/ml Dobutamine hydrochloride : 8 mg/ml	◆	1506
		Midazolam hydrochloride : 1 mg/ml Dopamine hydrochloride : 1,6 mg/ml	◆	176
		Midazolam hydrochloride : 1 mg/ml Dopamine hydrochloride : 3.2 mg/ml	◆	295
		Midazolam hydrochloride : 4 mg/ml Dopamine hydrochloride : 8 mg/ml	▲◆	1506
		Midazolam hydrochloride : 2 mg/ml Dopamine hydrochloride : 3.2 mg/ml		314
		Midazolam hydrochloride : 2 mg/ml Doripenem : 5 mg/ml	▲◆	2262
		Midazolam hydrochloride : 2.5 mg/ml Droperidol : 1.25 mg/ml	∅	404
		Midazolam hydrochloride : 2 mg/ml Epinephrine hydrochloride : 20 µg/ml		314
		Midazolam hydrochloride Eptifibatide		3934
		Midazolam hydrochloride : 1 mg/ml Eravacycline : 0,6 mg/ml	▲	4434
		Midazolam hydrochloride : 5 mg/ml Erythromycin lactobionate : 5 mg/ml	∅	186
		Midazolam hydrochloride : 1 mg/ml Esmolol hydrochloride : 40 mg/ml	◆	295
		Midazolam hydrochloride : 2.1 mg/ml Esmolol hydrochloride : 10 mg/ml	▲	3823
		Midazolam hydrochloride : 4 mg/ml Esomeprazole sodium : 0.32 mg/ml	▲◆	1506
		Midazolam hydrochloride : 5 mg/ml Etomidate : 2 mg/ml	∅	319
		Midazolam hydrochloride : 0.15 mg/ml Famotidine : 0.2 mg/ml	◆	398
		Midazolam hydrochloride : 1.5 mg/ml Famotidine : 2 mg/ml	▲	215
		Midazolam hydrochloride : 1 mg/ml Fenoldopam mesylate : 80 µg/ml	▲	1803
		Midazolam hydrochloride : 0,66 & 0,9 mg/ml Fentanyl citrate : 13 & 38 µg/ml	▲	929
		Midazolam hydrochloride : 5 mg/ml Fentanyl citrate : 50 µg/ml	∅	186
		Midazolam hydrochloride : 2 mg/ml Fentanyl citrate : 50 µg/ml		314
		Midazolam hydrochloride : 0.1 & 0.5 mg/ml Fentanyl citrate : 20 & 40 µg/ml	◆	225
		Midazolam hydrochloride : 1.67 mg/ml Fentanyl citrate : 33.33 µg/ml	∅	404
		Midazolam hydrochloride : 1 mg/ml Fentanyl citrate : 50 µg/ml	◆	176
		Midazolam hydrochloride : 0.2 mg/ml Fentanyl citrate : 25 µg/ml	◆	1974

		Midazolam hydrochloride : 5 mg/ml Flucloxacillin sodium : 50 mg/ml	∅	186
		Midazolam hydrochloride : 5 mg/ml Fluconazole : 2 mg/ml	∅	186
		Midazolam hydrochloride : 5 mg/ml Fluconazole : 2 mg/ml	▲	496
		Midazolam hydrochloride : 5 mg/ml Foscarnet sodium : 24 mg/ml	∅	73
		Midazolam hydrochloride : 1 mg/ml Fosfomycin : 30 mg/ml	▲◆	4055
		Midazolam hydrochloride : 2 mg/ml Fosphenytoin sodium : 5 mg/ml	▲	1419
		Midazolam hydrochloride : 1 mg/ml Furosemide : 10 mg/ml	◆	176
		Midazolam hydrochloride : 0.05 & 0.25 mg/ml Furosemide : 0.08 mg/ml	▲	1888
		Midazolam hydrochloride : 2 mg/ml Furosemide : 10 mg/ml		314
		Midazolam hydrochloride : 1 mg/ml Furosemide : 2,5 mg/ml	▲	4605
		Midazolam hydrochloride Furosemide		3465
		Midazolam hydrochloride : 0.1 & 0.5 mg/ml		232
		Midazolam hydrochloride Furosemide		3781
		Midazolam hydrochloride : 0.05 >> 0.4 mg/ml Gentamicin sulfate : 0.8 mg/ml	▲	1888
		Midazolam hydrochloride : > 0.6 mg/ml		232
		Midazolam hydrochloride : 2,1 mg/ml Furosemide : 10 mg/ml	∅	3134
		Midazolam hydrochloride : 0.48 mg/ml		3379
		Midazolam hydrochloride : 5 mg/ml Furosemide : 10 mg/ml	∅	186
		Midazolam hydrochloride : 2.5 mg/ml		3948
		Midazolam hydrochloride : 2 mg/ml		301
		Midazolam hydrochloride : 1 mg/ml	NaH CO3	176
		Midazolam hydrochloride : 5 mg/ml	NaH CO3	150
		Midazolam hydrochloride : 2,1 mg/ml	NaH CO3	3823
		Midazolam hydrochloride : 1 mg/ml Furosemide : 10 mg/ml	▲	4605
		Midazolam hydrochloride : 2,1 mg/ml Furosemide : 10 mg/ml	▲	3463
		Midazolam hydrochloride : 2,1 mg/ml Furosemide : 10 mg/ml	▲	3823
		Midazolam hydrochloride	NaH CO3	3466
		Midazolam hydrochloride : 5 mg/ml		939

		Midazolam hydrochloride : 5 mg/ml Gentamicin sulfate : 3 mg/ml	∅	186
		Midazolam hydrochloride : 1 mg/ml Gentamicin sulfate : 10 mg/ml	◆	176
		Midazolam hydrochloride : 2.5 mg/ml Glycopyrronium bromide : 0.1 mg/ml	∅	404
		Midazolam hydrochloride : 5 mg/ml Haloperidol lactate : 0.5 & 5 mg/ml	∅	186
		Midazolam hydrochloride : 0,04 & 0,08 mg/ml Haloperidol lactate : 0,12 >> 0,8 mg/ml	▲◆	4366
		Midazolam hydrochloride : 1.2 mg/ml Haloperidol lactate : 0.25 >> 0.5 mg/ml	▲◆	4404
		Midazolam hydrochloride : 2.1 mg/ml Haloperidol lactate : 0.5 mg/ml	▲	3823
		Midazolam hydrochloride : 5 mg/ml Heparin sodium : 417 UI/ml	∅	186
		Midazolam hydrochloride : 5 mg/ml Heparin sodium : 100 UI/ml		4389
		Midazolam hydrochloride : 2 mg/ml Heparin sodium : 100 UI/ml		314
		Midazolam hydrochloride : 2.5 mg/ml		3948
		Midazolam hydrochloride : 2.1 mg/ml Heparin sodium : 500 UI/ml	▲	3823
		Midazolam hydrochloride : 2 mg/ml		1415
		Midazolam hydrochloride : 5 mg/ml	RL	4603
		Midazolam hydrochloride : 1 mg/ml Glycerophosphate disodium	▲	4332
		Midazolam hydrochloride : 0.5 & 1.5 mg/ml Haloperidol lactate : 0.21 & 0.62 mg/ml	▲	1971
		Midazolam hydrochloride : 1 mg/ml Heparin sodium : 208,3 UI/ml	▲	4698
		Midazolam hydrochloride : 1 mg/ml Hetastarch : 60 mg/ml	Ⓡ	1721
		Midazolam hydrochloride : 5 mg/ml Human albumin : 200 mg/ml	∅	186
		Midazolam hydrochloride Hyaluronidase		3617
		Midazolam hydrochloride : 2 mg/ml Hydrocortisone sodium succinate : 1 mg/ml	▲	4550
		Midazolam hydrochloride : 1 mg/ml Hydrocortisone sodium succinate : 1 mg/ml	▲	4550
		Midazolam hydrochloride : 0.05 & 0.25 mg/ml Hydrocortisone sodium succinate : 0.05 mg/ml	▲	1888
		Midazolam hydrochloride : 5 mg/ml Hydrocortisone sodium succinate : 50 mg/ml	∅	186
		Midazolam hydrochloride : 0.2 mg/ml Hydromorphone hydrochloride : 0.5 mg/ml	◆	1974
		Midazolam hydrochloride : 0.1 >> 4.5 mg/ml Hydromorphone hydrochloride : 0.5 >> 45 mg/ml	▲◆	345
		Midazolam hydrochloride : 2 mg/ml Hydromorphone hydrochloride : 1 mg/ml		314

		Midazolam hydrochloride Hydroxocobalamin		3932
		Midazolam hydrochloride : 1.67 mg/ml Hydroxyzine dihydrochloride : 33.33 mg/ml	∅	404
		Midazolam hydrochloride : 1 mg/ml Ibuprofen lysinate : 10 mg/ml		4419
		Midazolam hydrochloride : 5 mg/ml Ibuprofen lysinate : 10 mg/ml		4419
24		Midazolam hydrochloride : 5 mg/ml Imipenem - cilastatin sodium : 5 mg/ml	∅	186
		Midazolam hydrochloride : 1 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Midazolam hydrochloride : 2.1 mg/ml Insulin : 2 UI/ml		3823
		Midazolam hydrochloride : 4 mg/ml Insulin : 1 UI/ml		1506
		Midazolam hydrochloride : 1 mg/ml Insulin : 1 UI/ml		295
		Midazolam hydrochloride : 1 & 5 mg/ml Insulin aspart : 1 UI/ml		1508
		Midazolam hydrochloride : 1 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Midazolam hydrochloride : 3.6 mg/ml Ketamine hydrochloride : 25 mg/ml		3705
		Midazolam hydrochloride : 5 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Midazolam hydrochloride : 1 mg/ml Labetalol hydrochloride : 5 mg/ml		295
		Midazolam hydrochloride : 2 mg/ml Labetalol hydrochloride : 2 mg/ml		314
		Midazolam hydrochloride : 2 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Midazolam hydrochloride : 1.2 mg/ml Levomepromazine : 0.625 >> 2.5 mg/ml		4404
		Midazolam hydrochloride : 5 mg/ml Levosimendan : 2,5 mg/ml		4389
		Midazolam hydrochloride : 2 mg/ml Linezolid : 2 mg/ml	∅	1925
		Midazolam hydrochloride : 2 mg/ml Lorazepam : 0.5 mg/ml		314
		Midazolam hydrochloride : 3.6 mg/ml Lormetazepam : 0.12 mg/ml		3705
		Midazolam hydrochloride : 1 mg/ml Meropenem : 50 mg/ml		4319
		Midazolam hydrochloride : 0.2 mg/ml Methadone hydrochloride : 1 mg/ml		1974
		Midazolam hydrochloride : 4 mg/ml Methadone hydrochloride : 0.2 mg/ml		1506
		Midazolam hydrochloride : 5 mg/ml Methotrexate sodium : 30 mg/ml		150
		Midazolam hydrochloride : 1 mg/ml Methylprednisolone sodium succinate : 40 mg/ml		176

		Midazolam hydrochloride : 1.2 mg/ml Metoclopramide hydrochloride : 3 mg/ml		4404
		Midazolam hydrochloride : 0.5 & 1.5 mg/ml Metoclopramide hydrochloride : 1.11 & 3.33 mg/ml		1971
		Midazolam hydrochloride : 1.67 mg/ml Metoclopramide hydrochloride : 3.33 mg/ml		404
		Midazolam hydrochloride : 0.05 >> 0.4 mg/ml Metronidazole : 5 mg/ml		1888
		Midazolam hydrochloride : 5 mg/ml Metronidazole : 5 mg/ml		186
		Midazolam hydrochloride : 1 mg/ml Metronidazole : 5 mg/ml		176
		Midazolam hydrochloride : 2 mg/ml Micafungin : 1.5 mg/ml		2108
		Midazolam hydrochloride : 2 mg/ml Milrinone lactate : 0.8 mg/ml		813
		Midazolam hydrochloride : 2 mg/ml Milrinone lactate : 0.2 mg/ml		314
		Midazolam hydrochloride : 1 >> 3 mg/ml Morphine hydrochloride : > 40 mg/ml		1866
		Midazolam hydrochloride : 1 >> 3 mg/ml Morphine hydrochloride : 10 >> 40 mg/ml		1866
		Midazolam hydrochloride : 1.2 mg/ml Morphine hydrochloride : 2 >> 5 mg/ml		4404
		Midazolam hydrochloride : 5 mg/ml Morphine hydrochloride : 1 mg/ml		186
		Midazolam hydrochloride : > 4 mg/ml Morphine hydrochloride : > 30 mg/ml		1866
		Midazolam hydrochloride : 0.5 & 1.5 mg/ml Morphine hydrochloride : 1.68 & 5 mg/ml		1971
		Midazolam hydrochloride : 2,5 mg/ml Morphine sulfate : 2,5 & 5 mg/ml		1492
		Midazolam hydrochloride : 2 mg/ml Morphine sulfate : 2 mg/ml		314
		Midazolam hydrochloride : 1 mg/ml Morphine sulfate : 1 mg/ml		295
		Midazolam hydrochloride : 0.2 mg/ml Morphine sulfate : 1 mg/ml		1974
		Midazolam hydrochloride : 2.5 mg/ml Morphine sulfate : 5 mg/ml		404
		Midazolam hydrochloride : 0,1 & 0,5 mg/ml Morphine sulfate : 0,25 & 1 mg/ml		86
		Midazolam hydrochloride : 5 mg/ml N-acetylcysteine : 200 mg/ml		3766
		Midazolam hydrochloride : 5 mg/ml Nafamostat : 10 mg/mL		4545
		Midazolam hydrochloride : 1 mg/ml Nafcillin sodium : 20 mg/ml		176
		Midazolam hydrochloride : 2.5 mg/ml Nalbuphine hydrochloride : 5 mg/ml		404
		Midazolam hydrochloride : 5 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408

		Midazolam hydrochloride : 2 mg/ml Nicardipine hydrochloride : 1 mg/ml		314
		Midazolam hydrochloride : 2.1 mg/ml Nimodipine : 0.2 mg/ml		3823
		Midazolam hydrochloride : 1 mg/ml Nitroglycerin : 0,2 mg/ml		176
		Midazolam hydrochloride : 1 mg/ml Nitroglycerin : 0.2 mg/ml		295
		Midazolam hydrochloride : 2 mg/ml Nitroglycerin : 0.4 mg/ml		314
		Midazolam hydrochloride : 2.1 mg/ml Nitroglycerin : 0.2 mg/ml		3823
		Midazolam hydrochloride : 1 mg/ml Nitroprusside sodium : 0,2 mg/ml		176
		Midazolam hydrochloride : 1 mg/ml Nitroprusside sodium : 0.2 mg/ml		295
		Midazolam hydrochloride : 4 mg/ml Norepinephrine bitartrate : 0.32 mg/ml		1506
		Midazolam hydrochloride : 2 mg/ml Norepinephrine bitartrate : 0.128 mg/ml		314
		Midazolam hydrochloride : 1 mg/ml Norepinephrine bitartrate : 0.064 mg/ml		295
		Midazolam hydrochloride : 5 mg/ml Omeprazole sodium : 4 mg/ml		186
		Midazolam hydrochloride : 2,1 mg/ml Omeprazole sodium : 1,6 mg/ml		3823
		Midazolam hydrochloride : 1.66 mg/ml Ondansetron hydrochloride : 1.33 mg/ml		815
		Midazolam hydrochloride : 1 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
		Midazolam hydrochloride : 0.8 & 2.5 mg/ml Oxycodone hydrochloride : 0.8 & 5 mg/ml		2125
		Midazolam hydrochloride : 2.9 & 3.3 mg/ml Oxycodone hydrochloride : 14.7 & 38.5 mg/ml		2900
		Midazolam hydrochloride : 0.8 & 2.5 mg/ml Oxycodone hydrochloride : 0.8 & 5 mg/ml		2125
		Midazolam hydrochloride : 2.9 & 3.3 mg/ml Oxycodone hydrochloride : 14.7 & 38.5 mg/ml		2900
		Midazolam hydrochloride : 2 mg/ml Palonosetron hydrochloride : 50 µg/ml		1975
		Midazolam hydrochloride : 0.05 mg/ml Pancuronium bromide : 0.05 mg/ml		402
		Midazolam hydrochloride : < 0.1 mg/ml Pantoprazole sodium : < 0.01 mg/ml		1902
		Midazolam hydrochloride : 0.1 mg/ml Pantoprazole sodium : 8 mg/ml		2139
		Midazolam hydrochloride Pantoprazole sodium		2090
		Midazolam hydrochloride : > 0.1 mg/ml Pantoprazole sodium : > 0.01 mg/ml		1902
		Midazolam hydrochloride : 5 mg/ml Paracetamol : 10 mg/ml		3571

		Midazolam hydrochloride : 5 mg/ml Paracetamol : 10 mg/ml		4435
		Midazolam hydrochloride : 5 mg/ml Paracetamol : 10 mg/ml		4742
		Midazolam hydrochloride : 1.67 mg/ml Pentobarbital sodium : 33.33 mg/ml	∅	404
		Midazolam hydrochloride : 0,12 mg/ml Pentoxifyllin : 5 mg/ml	▲	4543
		Midazolam hydrochloride : 0,5 mg/ml Pentoxifyllin : 5 mg/ml	▲	4538
		Midazolam hydrochloride : 2.5 mg/ml Pethidine hydrochloride : 50 mg/ml	∅	404
		Midazolam hydrochloride : 5 mg/ml Piperacillin sodium : 150 mg/ml	∅	186
		Midazolam hydrochloride : 3.6 mg/ml Piritramide : 1 mg/ml	▲	3705
		Midazolam hydrochloride : 1 mg/ml Plazomicin sulfate : 24 mg/ml	▲	4145
		Midazolam hydrochloride : 2.1 mg/ml Potassium chloride : 10 mEq/l	▲	3823
		Midazolam hydrochloride : 5 mg/ml Potassium chloride : 1000 mEq/l	∅	186
		Midazolam hydrochloride Potassium phosphate		3781
		Midazolam hydrochloride : 1.67 mg/ml Prochlorperazine edysilate : 1.67 mg/ml	∅	404
		Midazolam hydrochloride : 2.5 mg/ml Promethazine hydrochloride : 12.5 mg/ml	∅	404
		Midazolam hydrochloride : 0.3 mg/ml Propofol : 18.2 mg/ml	∅	4011
		Midazolam hydrochloride : 2 mg/ml Propofol : 10 mg/ml	∅	300
		Midazolam hydrochloride : 1 mg/ml Propofol		660
		Midazolam hydrochloride : 1.8 & 3.3 mg/ml Propofol : 1.8 & 10 mg/ml	∅	4011
		Midazolam hydrochloride : 5 mg/ml Propofol : 2 mg/ml	∅	319
		Midazolam hydrochloride : 0.05 & 0.25 mg/ml Ranitidine hydrochloride : 0.4 mg/ml	▲	1888
		Midazolam hydrochloride : 5 mg/ml Ranitidine hydrochloride : 0.5 mg/ml	∅	186
		Midazolam hydrochloride : 1.67 mg/ml Ranitidine hydrochloride : 16.67 mg/ml	∅	404
		Midazolam hydrochloride : 2 mg/ml Ranitidine hydrochloride : 1 mg/ml		314
		Midazolam hydrochloride : 2.1 mg/ml Remifentanil hydrochloride : 100 µg/ml	▲	3823
		Midazolam hydrochloride : 1 mg/ml Remifentanil hydrochloride : 120 µg/ml	◆	3176
		Midazolam hydrochloride : 1 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml	▲	59

		Midazolam hydrochloride : 4 mg/ml Remifentanil hydrochloride : 20 µg/ml		1506
		Midazolam hydrochloride : 1 mg/ml Remifentanil hydrochloride : 120 µg/ml		3294
		Midazolam hydrochloride : 5 mg/ml Remimazolam : 5 mg/ml		4723
		Midazolam hydrochloride : 2.1 mg/ml Rocuronium bromide : 10 mg/ml		3823
		Midazolam hydrochloride : 5 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Midazolam hydrochloride : 3.33 mg/ml Scopolamine hydrobromide : 0.287 mg/ml		404
		Midazolam hydrochloride : 0.5 & 1.5 mg/ml Scopolamine N-butyl bromide : 1.68 & 5 mg/ml		1971
		Midazolam hydrochloride : 1.2 mg/ml Scopolamine N-butyl bromide : 3-7 mg/ml		4404
		Midazolam hydrochloride : 5 mg/ml Sodium bicarbonate : 14 mg/ml		150
15'		Midazolam hydrochloride : 2.1 mg/ml Sodium bicarbonate : 84 mg/ml		3212
24		Midazolam hydrochloride : 0.1 & 0.5 mg/ml Sodium bicarbonate : 50 mg/ml		1888
24		Midazolam hydrochloride : 0.1 & 0.5 mg/ml Sodium bicarbonate : 50 mg/ml	NaH CO3	1888
?		Midazolam hydrochloride Sodium bicarbonate		3466
2		Midazolam hydrochloride : 1 mg/ml Sodium bicarbonate : 84 mg/ml		176
?		Midazolam hydrochloride : 2.1 mg/ml Sodium bicarbonate : 84 mg/ml		3823
		Midazolam hydrochloride : 3,6 mg/ml Sodium oxybate : 200 mg/ml		3705
		Midazolam hydrochloride : 1 mg/ml Sufentanil citrate : 0.005 mg/ml		3294
		Midazolam hydrochloride : 3.6 mg/ml Sufentanil citrate : 0.03 mg/ml		3705
		Midazolam hydrochloride : 5 mg/ml Sugammadex : 100 mg/ml		3372
		Midazolam hydrochloride : 1 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Midazolam hydrochloride : 5 mg/ml Temocilline : 83.33 mg/ml		2231
?		Midazolam hydrochloride Temocilline		4470
		Midazolam hydrochloride : 1 mg/ml Theophylline : 1,6 mg/ml		176
		Midazolam hydrochloride : 2 mg/ml Thiopental sodium : 25 mg/ml		314
		Midazolam hydrochloride : 5 mg/ml Thiopental sodium : 25 mg/ml		3767
?		Midazolam hydrochloride : 2,1 mg/ml Thiopental sodium : 60 mg/ml		3823

		Midazolam hydrochloride : 5 mg/ml Thiopental sodium : 25 mg/ml		319
		Midazolam hydrochloride : 0,05 & 5 mg/ml Tirofiban : 50 µg/ml		1603
		Midazolam hydrochloride Tirofiban		1512
		Midazolam hydrochloride : 1 mg/ml Tobramycin sulfate : 10 mg/ml		176
		Midazolam hydrochloride Tramadol hydrochloride		3521
		Midazolam hydrochloride : 0.5 & 1.5 mg/ml Tramadol hydrochloride : 11.18 & 33.3 mg/ml		1971
		Midazolam hydrochloride : 2.1 mg/ml Urapidil : 5 mg/ml		3823
		Midazolam hydrochloride : 2,1 mg/ml Valproic acid : 16 mg/ml		3823
		Midazolam hydrochloride : 2 mg/ml Valproic acid : 2 & 20 mg/ml		4428
		Midazolam hydrochloride : 5 mg/ml Vancomycin hydrochloride : 10 mg/ml		3385
		Midazolam hydrochloride : 1 mg/ml Vancomycin hydrochloride : 5 mg/ml		176
		Midazolam hydrochloride : 5 mg/ml Vancomycin hydrochloride : 5 mg/ml	∅	186
		Midazolam hydrochloride : 2 mg/ml Vecuronium bromide : 1 mg/ml		314
		Midazolam hydrochloride : 5 mg/ml Vecuronium bromide : 4 mg/ml	∅	186
		Midazolam hydrochloride : 0.05 mg/ml Vecuronium bromide : 0.1 mg/ml		402

Voie d'administration

Bibliographie

	Type	Source
5	Revue	Stiles ML, Allen LV Jr, Prince SJ. Stability of deferoxamine mesylate, floxuridine, fluorouracil, hydromorphone hydrochloride, lorazepam, and midazolam hydrochloride in polypropylene infusion-pump syringes. Am J Health-Syst Pharm 1996 ; 53: 1583-1588.
41	Revue	Pramar YV, Loucas VA, El-Rachidi A. Stability of midazolam hydrochloride in syringes and IV fluids. Am J Health-Syst Pharm 1997 ; 54: 913-915.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.

73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
86	Revue	Johnson CE, Bhatt-Mehta V, Mancari SC, McKown JA. Stability of midazolam hydrochloride and morphine sulfate during simulated intravenous coadministration. Am J Hosp Pharm 1994 ; 51: 2812-2815.
93	Revue	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
150	Revue	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
176	Revue	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
185	Revue	McMullin ST, Burns Schaiff RA, Dietzen DJ. Stability of midazolam hydrochloride in polyvinyl chloride bags under fluorescent light. Am J Health-Syst Pharm 1995 ; 52: 2018-2020.
186	Revue	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
225	Revue	Bhatt-Mehta V, Johnson CE, Leininger N, Agarwal M. Stability of fentanyl citrate and midazolam hydrochloride during simulated intravenous coadministration. Am J Health-Syst Pharm 1995 ; 52: 511-513.
231	Revue	Hagan RL, Jacobs III LF, Pimsler M, Merritt GJ. Stability of midazolam hydrochloride in 5% dextrose injection or 0.9% sodium chloride injection over 30 days. Am J Hosp Pharm 1993 ; 50: 2379-2381.
232	Revue	Bhatt-Mehta V, Rosen DA, King RS, Marsym CJ. Stability of midazolam hydrochloride in parenteral nutrient solutions. Am J Hosp Pharm 1993 ; 50: 285-288.
285	Revue	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
295	Revue	Yamashita SK, Walker SE, Choudhury T, Iazzetta J. Compatibility of selected critical care drugs during Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
314	Revue	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.

319	Revue	Hadzija BW, Lubarsky DA. Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. Am J Health-Syst Pharm 1995 ; 52: 997-999.
345	Revue	Walker SE, Meinders A, Tailor H. Stability and compatibility of reconstituted sterile hydromorphone with midazolam. Can J Hosp Pharm 1996 ; 49: 290-298.
350	Revue	Martens HJ, De Goede PN, Van Loenen AC. Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers. Am J Hosp Pharm 1990 ; 47: 369-373.
398	Revue	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
399	Revue	Bleasel MD, Peterson GM, Jestrimski KW. Stability of midazolam in sodium chloride infusion packs. Aust J Hosp Pharm 1993 ; 23: 260-262.
401	Revue	Peterson GM, Khoo BHC, Galloway JG, Paterson J. A preliminary study of the stability of midazolam in polypropylene syringes. Aust J Hosp Pharm 1991 ; 21: 115-118.
402	Revue	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
404	Revue	Forman JK, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987 ; 44: 2298-2299.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
813	Revue	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
815	Revue	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL. Stability of ondansetron hydrochloride and 12 medications in plastic syringes. Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
865	Revue	Bhatt-Mehta V, Hirata S. Physical compatibility and chemical stability of atracurium besylate and midazolam hydrochloride during intravenous coinfusion. Int J Pharm Compound 1998 ; 2: 79-81.
896	Revue	Bianchi C, Airaudo CB, Gayte-Sorbier A. Sorption studies of dipotassium clorazepate salt (Tranxene®) and midazolam hydrochloride (Hypnovel®) in polyvinyl chloride and glass infusion containers. J Clin Pharm Ther 1992 ; 17: 223-227.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.

929	Revue	Wilson KM, Schneider JJ, Ravenscroft PJ. Stability of midazolam and fentanyl in infusion solutions. J Pain Symptom Manage 1998 ; 16: 52-58.
939	Revue	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
1067	Revue	Zeidler C, Dettmering D, Schrammel W, Spieteller M. Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: 106-110.
1288	Revue	Allwood MC, Brown PW, Lee M. Stability of injections containing diamorphine and midazolam in plastic syringes. Int J Pharm Pract 1994 ; 3: 57-59.
1405	Revue	Peterson GM, Miller KA, Galloway JG, Dunne PF. Compatibility and stability of fentanyl admixtures in polypropylene syringes. J Clin Pharm Ther 1998 ; 23: 67-72.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1419	Revue	Riggs RM, English BA, Webster AA, McGuire JM, Riordan JM. Fosphenytoin Y-site stability studies with lorazepam and midazolam hydrochloride. Int J Pharm Compound 1999 ; 3: 235-238.
1492	Revue	LeBelle MJ, Savard C, Gagnon A. Compatibility of morphine and midazolam or haloperidol in parenteral admixtures. Can J Hosp Pharm 1995 ; 48: 155-160.
1506	Revue	Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112.
1508	Revue	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1512	Laboratoire	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015
1603	Revue	Bergquist PA, Manas D, Hunke WA, Reed RA. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs. Am J Health-Syst Pharm 2001 ; 58: 1218-1223.
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1637	Revue	Wong AH, Law S, Walker SE, Bowles SK. Concentration-dependant compatibility and stability of dexamethasone and midazolam. Can J Hosp Pharm 2000 ; 53: 24-31.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.

1759	Revue	Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1866	Revue	Vermeire A, Remon JP. Compatibility and stability of morphine in binary admixtures with haloperidol, midazolam, dexamethasone or methylprednisolone. Int J Pharm 1998 ; 174: 157-177.
1887	Revue	Andersin R, Tammilehto S. Photochemical decomposition of midazolam. IV . Study of pH dependant stability by high-performance liquid chromatography. Int J Pharm 1995 ; 123: 229-235.
1888	Revue	Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A. Compatibility study of midazolam. Ziekenhuisfarmacie 1986 ; 2: 45-48.
1901	Revue	Good PD, Schneider JJ, Ravenscroft PJ. The compatibility and stability of midazolam and dexamethasone in infusion solutions. J Pain Symptom Manage 2004 ; 27, 5: 471-475.
1902	Revue	Walker SE, Wyllie A, Law S. Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1944	Revue	Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health-Syst Pharm 2004 ; 61: 1774.
1964	Revue	Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
1971	Revue	Azuara ML, Sanchez Y, Reyes R, Barcia E. Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2001
1974	Revue	Chandler SW, Trissel LA, Weinstein SM Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility. J Pain Symptom Manage 1996 ; 12, 3: 168-171.
1975	Revue	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with lorazepam and midazolam hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 235-237.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2018	Revue	Veggeland T. Visual compatibility of clonidine with selected drugs. Am J Health-Syst Pharm 2005 ; 62: 1968-1969.

2083	Revue	La Forgia SP, Sharley NA, Burgess NG, Doecke CJ. Stability and compatibility of morphine, midazolam and bupivacaine combinaisons for iontravenous infusion. J Pharm Pract and Res 2002 ; 32: 65-68.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2125	Revue	Gardiner PR. Compatibility of an injectable oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration. Hospital Pharmacist 2003 ; 10: 354-361.
2139	Revue	Serrurier C, Chenot ED, Vigneron J, May I, Demor? B. Assessment of injectable drug's administration in two intensive care units and determination of potential physico-chemical incompatibilities. EJHP Science 2006 ; 12,5: 96-99.
2141	Revue	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2166	Revue	Nassr S, Dubuc MC, Lavoie P, Brazier JL. HPLC-DAD methods for studying the stability of solutions containing hydromorphone, ketorolac, haloperidol, midazolam, famotidine, metoclopramide, dimenhydrinate and scopolamine. J Liquid Chrom Rel Technol 2003 ; 26, 17: 2909-2929.
2231	Revue	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2376	Revue	de Diego M, Godoy G, Mennikent S. Chemical stability of midazolam injection by high performance liquid chromatography. J Sep Sci 2007 ; 30, 12: 1233-1238.
2900	Revue	Hines S, Pleasance S. Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings,infusion bags and drugs for potential co-administration. EJHP 2009 ; 15, 5: 32-38.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.

3134	Revue	Perez Jua En, Maqueda Palau M, Arévalo Rubert Mt, Ribas Nicolau B, Amoros Cerdà SM. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ; 21: 96-103.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3176	Poster	Humbert Delaloye V, Berger M, Voirol P, Pannatier A. Compatibilité du Remifentanil avec d'autres médicaments injectables : influence du soluté. 16èmes JFSPH, Sion, 18-19 novembre 2010
3212	Revue	Ribas Nicolau, B.; P?rez Juan, E.; Amor?s Cerd?, S.M.; Ar?valo Rubert, M.J.; Maqueda Palau, M. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos. Enferm Intensiva 2011 ;22:78-82.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3222	Revue	Karlage K, Earhart Z, Green-Boesen K, . Myrdal PB Stability of midazolam hydrochloride injection 1-mg/mL solutions in polyvinyl chloride and polyolefin bags Am J Health-Syst Pharm 2011 ;68:1537-1540.
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3294	Revue	Humbert-Delaloye V, Berger M, Voirol P, Pannatier A. In vitro compatibility of remifentanil hydrochloride and sufentanil citrate with selected drugs EJHP 2012 ; 19: 57-64.
3372	Revue	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3379	Revue	Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524.
3385	Revue	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3463	Revue	Eva Perez Juan, Maria Jos? Arévalo Rubert , Silvia Monica Amoros Cerda , Palau M.M, Nicolau B.R. Fármacos en perfusión continua en la unidad de cuidados intensivos: estudio de compatibilidad. Nursing 2011 ; 29 :62-6
3464	Revue	Monica Maqueda-Palau, Eva Pérez-Juan, Maria Josep Arévalo-Rubert, Sylvia Monica Amoros-Cerda, Bàrbara Ribas-Nicolau. Compatibilidad física de la amiodarona en perfusión continua Enferm Clin 2011 21:25-29.
3465	Revue	E. P?rez Juan, M. Maqueda Palau, M. Ar?valo Rubert, B. Ribas Nicolau, S.M. Amor?s Cerd?. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ;21:96-103.
3466	Revue	B. Ribas Nicolau, E. P?rez Juan, S.M. Amor?s Cerd?, M.J. Ar?valo Rubert, M. Maqueda Palau. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos Enferm Intensiva 2011 ;22:78-82.
3521	Laboratoire	Tramadol® - Summary of Product Characteristics. Beacon Pharmaceuticals 2012

3571	Revue	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3601	Laboratoire	Cisatracurium Actavis - Résumé des Caractéristiques du Produit Actavis 2012
3617	Laboratoire	Hyaluronidase (Hyalase®) - Summary of Product Characteristics Wockhardt 2011
3705	Revue	Knudsen L, Eisend S, Haake N, Kunze T. Physicochemical compatibility of commonly used analgesics and sedatives in the intensive care medicine. EJHP 2014 ;21:161-166
3728	Revue	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3781	Revue	Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier A Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide. EJHP 2015 ;22:1 56-58
3823	Revue	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l'unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3932	Laboratoire	Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015
3934	Laboratoire	Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 2016
3948	Revue	Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416?424.
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.

3976	Revue	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
3989	Revue	Feutry F, Genay S, Velghe C, Barthélémy C, Décaudin B, Odou, P. Stability of midazolam and noradrenaline stored in cyclic olefin copolymer AT-Closed Vials® and polypropylene syringes during 365 days. Pharmaceutical Technology in Hospital Pharmacy 2017 ; 2,1: 35
4011	Revue	Gersonde F, Eisend S, Haake N, Kunze T. Physicochemical compatibility and emulsion stability of propofol with commonly used analgesics and sedatives in an intensive care unit. EJHP 2016 2016;0:1-11
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4119	Poster	Marcoz N, Ing H, Sautter AM, Saadi JF, Roulin JF, Bonnabry P. Stabilité et compatibilité de solutions injectables d'amiodarone (Cordarone®) Hôpitaux Universitaire de Genève 2004
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4201	Revue	Gilliot S, Masse M, Feutry F, Barthélémy C, Décaudin B, Genay S, Odou P. Long-term stability of ready-to-use 1-mg/mL midazolam solution. Am J Health-Syst Pharm 2020 ; 77, 9: 681-689.
4303	Revue	Anderson C, MacKay M. Stability of Fentanyl Citrate, Hydromorphone Hydrochloride, Ketamine Hydrochloride, Midazolam, Morphine Sulfate, and Pentobarbital Sodium in Polypropylene Syringes. Pharmacy 2015 3, 379-385.
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4332	Poster	Compatibilité de Glycophos® avec d'autres médicaments administrés en perfusion aux soins intensifs (SI) Compatibilité de Glycophos® avec d'autres médicaments administrés en perfusion aux soins intensifs (SI). JFSPH 2019 2019
4366	Revue	Estan-Cerezo G, Rodriguez-Lucena F.J, Matoses Chirivella C, Jiminez-Pulido I, Garcia-Monsalve A, Navarro-Ruiz A. Midazolam and haloperidol for palliative sedation: physicochemical stability and compatibility of parenteral admixtures. Braz J Pharm Sci 2019 ;55:e17351
4389	Revue	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4404	Poster	Müller U, Haller F, Wiedemeier P, Steuer C. Compatibility studies of seven commonly used drugs for parenteral administration in palliative care. JFSPH 2019 2019
4419	Revue	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4428	Revue	Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J. Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma. J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132.

4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4435	Revue	Hanifah S, Nugroho B.H, Chabib L. Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection. Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27.
4470	Revue	Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P. Continuous versus intermittent infusion of temocillin in intensive care unit patient. Critical care 2005 ; 9(Suppl 1) P37
4491	Revue	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2020
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4538	Revue	Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K. Compatibility of pentoxifylline and parenteral medications. Archives of Disease in Childhood 2020 ; 105: 395-397.
4543	Revue	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4545	Revue	Kondo M, Nagano M, Yoshida M, Yoshida N, Tagui N, Yoshida M, Sugaya K, Takase H. Physical compatibility of nafamostat with analgesics, sedatives, and muscle relaxants for coronavirus disease treatment. Journal of Nippon Medical school 2021
4550	Revue	Semark, A.J, Venkatesh, K, McWhinney B.C, Pretorius, C, Roberts, J.A, Cohen J, Venkatesh B. The compatibility of a low concentration of hydrocortisone sodium succinate with selected drugs during a simulated Y-site administration. Crit Care Resusc 2013 ;15, 1: 63–66.
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4605	Revue	Foinard A, Décaudin B, Barthélémy C, Debaene B, Odou P. Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility. Ann Allergy 2012 ; 2:28.
4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4651	Revue	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2021 ;180,1169–1176.
4654	Poster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4698	Revue	Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022

4723	Revue	Kondo M, Yoshida N, Yoshida M, Tanaka C, Tagami T, Horik K, Sugaya K, Takase H Physical compatibility of remimazolam with opioid analgesics, sedatives, and muscle relaxants during simulated Y-site administration. Am J Health-Syst Pharm 2022 https://doi.org/10.1093/a
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4802	Laboratoire	Glucose-1-Phosphate disodique tétrahydraté (Phocytan®) - Résumé des caractéristiques du produit Aguettant Laboratory 2021

Stabilis

Midazolam hydrochloride



Stabilité des préparations

	150 mg Dormicum®	Nipagin® 60 mg Nipasol® 120 mg Sirop simple >> 60 mL	-15°C		60			3488
	150 mg Dormicum®	Nipagin® 60 mg Nipasol® 120 mg Sirop simple >> 60 mL	2-8°C	±	60			3488
	45 mg Versed®	Syrpalta® >> 18 ml	20°C		56			2499
	150 mg Dormicum®	Nipagin® 60 mg Nipasol® 120 mg Sirop simple >> 60 mL	25°C	±	60			3488
	75 mg (5 mg/ml) ®=?	Sirop simple 14.5 ml Essence de menthe 0.5 ml	25°C		14			2772
	90 mg (5 mg/ml) ®=?	Sirop simple 11.4 ml Essence de menthe 0,6 ml	25°C		14			2772
	45 mg Versed®	Syrpalta® >> 18 ml	40°C		56			2499

		45 mg Versed®	Syrpalta® >> 18 ml	4°C		56				2499
		150 mg Dormicum®	Nipagin® 60 mg Nipasol® 120 mg Sirop simple >> 60 mL	-15°C		60				3488
5 mg/mL - 10 mL)	® = ?	(APP Pharmaceuticals)	Eau purifiée 15 mL SyrSpend SF® >> 50 mL	2-8°C		58				3437
5 mg/mL - 10 mL)	® = ?	(APP Pharmaceuticals)	Eau purifiée 15 mL SyrSpend SF Cherry® >> 50 mL	2-8°C		58				3437
		150 mg Dormicum®	Nipagin® 60 mg Nipasol® 120 mg Sirop simple >> 60 mL	2-8°C		60				3488
		500mg Versed®	Sirop simple 50ml Teinture d'orange 0,12ml Colorant rouge Colorant jaune Eau distillée >>100ml	23°C	?	102				2575
5 mg/mL - 10 mL)	® = ?	(APP Pharmaceuticals)	Eau purifiée 15 mL SyrSpend SF Cherry® >> 50 mL	25°C		58				3437
5 mg/mL - 10 mL)	® = ?	(APP Pharmaceuticals)	Eau purifiée 15 mL SyrSpend SF® >> 50 mL	25°C		58				3437
		150 mg Dormicum®	Nipagin® 60 mg Nipasol® 120 mg Sirop simple >> 60 mL	25°C		60				3488

Bibliographie

	Type	Source
2499	Revue	Steedman SL, Koonce, JR, Wynn JE, Brahen NH. Stability of midazolam hydrochloride in a flavored, dye-free oral solution Am J Hosp Pharm 1992 ; 49: 615-618.
2575	Revue	Walker SE, Grad HA, Haas DA, Mayer A. Stability of parenteral midazolam in an oral formulation. Anest Prog 1997 ; 44, 1: 17-22.
2772	Revue	Gragory DF, Koestner JA, Tobias JD. Stability of midazolam prepared for oral administration South Med J 1993 ; 86: 771-772.
3437	Revue	Geiger C.M, Sorenson B, Whaley P.A. Stability of Midazolam in SyrSpend SF and SyrSpend SF Cherry. Int J Pharm Compound 2013 ; 17, 4: 344-346.
3488	Revue	Caldes R, Ciges S.M, Borras E, Calvelo R, Lisart F. Jarabe de midazolam: Estudio de estabilidad de una solucion oral para uso hospitaliaro. Farm Hosp 1995 ; 19, 1: 41-44.

Stabilis

Midazolam hydrochloride



Stabilité des préparations

?		1 mg ® = ?	Cellulose microcristalline 100 mg	22-25°C		365			4520

Bibliographie

	Type	Source
4520	Revue	Boivin P-N, Legendre P, Bonnaure A-C, M-A. Physicochemical stability of compounded midazolam capsules over a one-year storage period. Pharmaceutical Technology in Hospital Pharmacy 2020

Dictionnaire

	Anxiolytique		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Verre
	NaCl 0,9% ou glucose 5%		A l'abri de la lumière
	Heure		Jour
	Chlorure de sodium 0,9%		Glucose 5%
	Avec ou sans lumière	PVC	Polyvinyl chlorure
PE	Polyéthylène	POF	Polyolefine
	Seringue polypropylène	?	Non précisée
	Lumière	∅	Aucun
	AT-Closed vial®		Stabilité en mélange
	Solvant		Molécule
PP	Polypropylène		Eau pour préparation injectable
?	Non précisé		Facteur influençant la stabilité
	Provoque		Dégradation
	Nutrition parentérale (mélange ternaire)		Nutrition parentérale (mélange binaire)
NaH CO3	NaHCO3		Diminution
	Augmentation stabilité		Précipitation
	Compatibilités		Compatible
	Précipitation immédiate		Incompatible
	Turbidité immédiate		Changement de couleur
	Instabilité chimique	RL	Ringer lactate
	Turbidité en 1 heure		Incompatibilité non précisée
	Précipitation en 8 heures		Changement de couleur en 24 heures
	Précipitation en 2 heures		Dégagement gazeux
	Instabilité de l'émulsion immédiate		Solvant spécifique

	Turbidité à 24 heures		Incompatibilité subvisuelle
	Instabilité de l'émulsion à 6 heures		Précipitation en 15 minutes
	Voie d'administration		Intraveineuse
	Perfusion continue		Intramusculaire
	Sous cutanée		Perfusion SC continue
	Bibliographie		Solution buvable
	Stabilité des préparations		Origine
	Excipient		Flacon injectable
	Flacon plastique		Gélule
	Poudre		Dictionnaire